AIRLINK 65.90 Decreased By ▼ -0.90 (-1.35%)
BOP 5.69 Increased By ▲ 0.02 (0.35%)
CNERGY 4.65 Increased By ▲ 0.02 (0.43%)
DFML 22.85 Increased By ▲ 0.53 (2.37%)
DGKC 70.70 Increased By ▲ 0.94 (1.35%)
FCCL 20.35 Increased By ▲ 0.73 (3.72%)
FFBL 29.11 Decreased By ▼ -1.09 (-3.61%)
FFL 9.93 Increased By ▲ 0.03 (0.3%)
GGL 10.08 Increased By ▲ 0.03 (0.3%)
HBL 115.25 Decreased By ▼ -0.45 (-0.39%)
HUBC 129.50 Decreased By ▼ -1.01 (-0.77%)
HUMNL 6.70 Decreased By ▼ -0.04 (-0.59%)
KEL 4.38 Increased By ▲ 0.03 (0.69%)
KOSM 5.02 Increased By ▲ 0.22 (4.58%)
MLCF 36.96 Decreased By ▼ -0.23 (-0.62%)
OGDC 131.20 Decreased By ▼ -2.35 (-1.76%)
PAEL 22.48 Decreased By ▼ -0.12 (-0.53%)
PIAA 26.30 Decreased By ▼ -0.40 (-1.5%)
PIBTL 6.53 Increased By ▲ 0.28 (4.48%)
PPL 112.12 Decreased By ▼ -1.83 (-1.61%)
PRL 28.39 Increased By ▲ 1.24 (4.57%)
PTC 16.11 Decreased By ▼ -0.02 (-0.12%)
SEARL 58.29 Decreased By ▼ -1.41 (-2.36%)
SNGP 65.69 Decreased By ▼ -0.81 (-1.22%)
SSGC 11.02 Decreased By ▼ -0.19 (-1.69%)
TELE 8.94 No Change ▼ 0.00 (0%)
TPLP 11.53 Increased By ▲ 0.19 (1.68%)
TRG 69.24 Decreased By ▼ -0.12 (-0.17%)
UNITY 23.95 Increased By ▲ 0.50 (2.13%)
WTL 1.35 Decreased By ▼ -0.01 (-0.74%)
BR100 7,304 Decreased By -13.1 (-0.18%)
BR30 23,950 Decreased By -155.6 (-0.65%)
KSE100 70,333 Decreased By -150.3 (-0.21%)
KSE30 23,121 Decreased By -82 (-0.35%)

Pakistan to get COVID-19 vaccine from China to conduct clinical trials

  • State-owned China National Pharmaceutical Group, commonly known as Sinopharm, has teamed up with Karachi University’s International Centre for Chemical and Biological Sciences to hold the trials in Pakistan
Published August 14, 2020

(Karachi) Pakistan will receive coronavirus vaccine from China, one of its closest allies, to vaccinate the most vulnerable among its population, including the elderly, healthcare workers and people with medical conditions associated with serious cases of Covid-19, as per a report in the Wall Street Journal.

China has reached one of its first agreements to test its coronavirus vaccine in populations beyond its borders.

The publication stated about one-fifth of the country’s population could be covered by the allocation while Pakistan is also negotiating with another Chinese company to conduct trials of its vaccine in the country.

"China hasn’t been a major vaccine producer globally. It needs to test its COVID-19 vaccines outside its borders because coronavirus cases in China have dwindled and it is harder to find the population diversity required," read the report.

The publication reported that the state-owned China National Pharmaceutical Group, commonly known as Sinopharm, has teamed up with Karachi University’s International Centre for Chemical and Biological Sciences to hold the trials in Pakistan.

“Pakistan would get the vaccine on a priority basis,” an official involved in forging the pact told the Wall Street Journal. However, the official clarified that the financial terms of the deal are yet to be finalised.

Pakistan will conduct Phase 1 trials of the vaccine and then move rapidly to the final stage Phase 3 trial. The final phase would require tens of thousands of volunteers. China has developed three coronavirus vaccines which are in the Phase 3 trials.

Comments

Comments are closed.